The reasons why plasma tau, particularly p‐tau (p‐tau217, p‐tau231, and p‐tau181), remains a robust biomarker for AD despite potential for proteolytic cleavage are not fully understood. This evidence concerns the gene MAPT and Alzheimer disease.